106 STAT. 4504 PUBLIC LAW 102-571—OCT. 29, 1992

and Commerce of the House of Representatives and the
Committee on Labor and Human Resources of the Senate
a final report containing the findings resulting from the
study and the recommendations described in subparagraph
(B).

(B) RECOMMENDATIONS.—Such report shall contain the
recommendations described in paragraph (1)(B).

SEC. 206. SAFETY AND REGULATORY OUTCOMES STUDY.

(a) SAFETY STUDY.—The Director of the Office of Technology
Assessment, in cooperation with the Congressional Research Service
and subject to the approval of the Technology Assessment Board,
shall conduct a study of the relationship between—

(1) regulatory systems affecting the development and sale
of dietary supplements of vitamins, minerals, herbs, or other
similar nutritional substances; and

(2) health outcomes.

(b) CONTENTS.—

(1) IN GENERAL.—In carrying out the study, the Director
of the Office of Technology Assessment shall examine the efforts
of industrialized nations (including the United States) to regu-
late the manufacture and sale of such dietary supplements
and the effect of the regulatory efforts on human health.

(2) INFORMATION.—The study shall include information
regarding—

(A) whether and how other countries regulate products
that are regulated as such dietary supplements in the
United States;

(B) the classification systems used in regulating such
products, such as systems that classify such supplements
by safety, function, source, usage, dose, or other character-
istics;

(C) the effect of the classification on the regulation
of the supplements;

(D) how safety concerns, including safety concerns at
the time of manufacture and sale of the product are
addressed by the regulatory process;

(E) how deception concerns (including misbranding)
are addressed by the regulatory process; and

(F) the labeling requirements, if any, for the sale of
the products.

(3) ANALYSIS.—The study shall also examine—

(A) whether there are disparate rates of morbidity
and mortality associated with the consumption of such
dietary supplements among nations;

(B) whether particular regulatory systems may be asso-
ciated with lower morbidity and mortality rates; and

(C) whether a causal relationship may be demonstrated
between the regulatory system used and the health out-
comes of the populations affected.